Avastin is approved to treat glioblastoma (GBM) when taken alone in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM). The effectiveness of Avastin in rGBM is based on tumor response. Currently, no data have shown whether or not Avastin improves disease-related symptoms or survival in people with rGBM.
Metastatic Colorectal Cancer (mCRC)
Avastin is approved to treat metastatic colorectal cancer (mCRC) for:
- First- or second-line treatment in combination with intravenous 5-fluorouracil–based chemotherapy
- Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes Avastin
Avastin is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.
Non–Small Cell Lung Cancer (nsNSCLC)
Avastin, in combination with carboplatin and paclitaxel, is approved to treat advanced nonsquamous non–small cell lung cancer (nsNSCLC) in people who have not received chemotherapy for their advanced disease.
Metastatic Kidney Cancer (mRCC)
Avastin, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).
Recurrent Platinum-Treated Ovarian Cancer (rOC)
Avastin in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (prOC) in women who received no more than two prior chemotherapy treatments. Avastin, either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by Avastin alone, is approved for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (psOC).
Advanced Cervical Cancer (CC)
Avastin, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.